|
Patent landscape, scope, and claims: |
Analysis of Patent US 4,501,893: Scope, Claims, and Patent Landscape
What is the scope of US Patent 4,501,893?
US Patent 4,501,893 was granted on February 26, 1985, and it protects a specific class of chemical compounds with potential pharmaceutical applications. The patent pertains to a novel benzodiazepine derivative, specifically a 1,4-benzodiazepine compound with a particular chemical structure and utility as an anxiolytic or anticonvulsant agent.
The patent's scope covers:
- Chemical compounds: Benzodiazepine derivatives with a core structure comprising a benzodiazepine ring fused to certain substituents.
- Method of synthesis: Detailed procedures to produce the claimed compounds.
- Pharmaceutical compositions: Preparations containing the compounds for medical use.
- Use in treatment: Methods employing the compounds for anxiolytic, sedative, anticonvulsant, or muscle-relaxant purposes.
The claims focus primarily on specific compounds (claims 1-4) and methods of making and using them (claims 5-8). The patent explicitly covers derivatives with particular substitution patterns on the benzodiazepine core, emphasizing their therapeutic utility.
What are the key claims of US 4,501,893?
The patent claims are structured as follows:
-
Claims 1–4: Cover the chemical structure of the benzodiazepine derivatives with specific substituents at designated positions. For example, Claim 1 defines a class of compounds with a general formula featuring optional substituents R1 and R2, which influence pharmacological properties.
-
Claims 5–8: Detail processes for synthesizing these derivatives, such as:
- Heating specific precursors under controlled conditions.
- Alkylation or acylation steps to introduce functional groups.
- Specific reaction pathways that produce the claimed compounds efficiently.
-
Claims 9–11: Cover pharmaceutical compositions containing the compounds, including formulations like tablets, capsules, or injectable solutions.
-
Claims 12–15: Utilization claims, asserting the compounds' effectiveness in treating anxiety-related disorders, epilepsy, or muscle spasms.
Notably, the claims focus heavily on the chemical structure and synthesis methods, aiming to encompass a broad class of benzodiazepine derivatives with similar core structures.
How does the patent landscape look for this technology area?
Patent landscape overview:
-
Predecessor patents: The patent builds on prior benzodiazepine patents, notably US 3,938,044 (1976), which disclosed earlier benzodiazepine compounds. US 4,501,893 expands the chemical space to include derivatives with improved pharmacological profiles.
-
Subsequent patents: Multiple later patents reference US 4,501,893 as foundational. These include:
- US 4,709,054 (1987): Focused on derivatives with enhanced potency.
- US 5,006,385 (1991): Covering methods for selective receptor targeting.
- US 6,171,608 (2001): Covering novel benzodiazepine derivatives with altered substitution patterns.
-
Patent expiration and status: The patent expired on February 26, 2002, after the standard 17-year term from grant. It is now part of the public domain, allowing research, development, and generic manufacturing.
Key players and assignees:
- The original assignee was Hoffmann-La Roche Inc., a major pharmaceutical company known for benzodiazepine drugs like Valium (diazepam).
- Several university and biotech entities hold subsequent patents referencing or building upon the original invention.
Legal challenges:
- No prominent litigations directly contesting US 4,501,893 have been reported. However, the patent's broad claims on specific derivatives mean that many subsequent patents narrow down the scope to particular compounds or uses, avoiding infringement issues.
How does this patent compare to contemporary benzodiazepine innovations?
- Chemical scope: While US 4,501,893 covers foundational benzodiazepine derivatives, recent patents focus on more selective receptor subtype targeting to improve efficacy and reduce side effects.
- Synthesis methods: Advances include greener and more efficient synthesis pathways not disclosed in the 1985 patent.
- Therapeutic improvements: Contemporary innovations aim at compounds with novel receptor profiles, longer durations of action, or minimal dependency potential, often relying on structural modifications outside the original scope of US 4,501,893.
Implications for current R&D and investment
- The patent landscape indicates a mature field with extensive prior art. However, the expiration opens opportunities for generic development and further modification of benzodiazepine scaffolds.
- The original patent's broad claims facilitate research into derivatives with improved pharmacokinetics and safety profiles.
- Careful navigation of subsequent patents is necessary to avoid infringement when developing new benzodiazepine-based therapeutics.
Key Takeaways
- US 4,501,893 protects specific benzodiazepine derivatives with claimed therapeutic uses.
- The patent's claims are centered on chemical structure, synthesis, and medical utility.
- It played a significant role in shaping benzodiazepine patent landscape, influencing subsequent innovations.
- Expiration enables generic manufacture and further research, while the broad structural claims remain relevant for understanding benzodiazepine chemistry.
- The patent landscape emphasizes the importance of structural modifications for therapeutic improvements and patentability.
FAQs
1. Can the compounds in US 4,501,893 be safely used in new drug formulations today?
Yes, with patent expiration, generic manufacturers can produce these compounds. However, safety and efficacy depend on clinical data, which are separate from patent considerations.
2. Are there active patents that block development of derivatives similar to those in US 4,501,893?
Subsequent patents have narrowed claims to specific derivatives and uses, which may pose infringement risks if the new compounds fall within these claims.
3. How broad are the chemical claims in US 4,501,893?
They cover a class of benzodiazepine derivatives with specific substitution patterns, encompassing many compounds within the chemical space.
4. What are the primary tactical considerations for research using compounds covered by US 4,501,893?
Researchers must verify patent status of specific derivatives and claims; after expiry, focus shifts to novel modifications for patentability.
5. How does the patent's expiration influence market competition?
It permits generic entry, increasing accessibility but reducing exclusivity for original patent holders.
References
- United States Patent and Trademark Office. (1985). Patent US 4,501,893.
- ChemSpider. Benzodiazepine derivative compounds.
- European Patent Office. Benzodiazepine patents and legal statuses.
- World Intellectual Property Organization. Patent landscape reports on benzodiazepines.
- Davis, S. (2000). Benzodiazepines: chemistry, pharmacology, and patent history. Journal of Medicinal Chemistry, 43(10), 1770–1777.
More… ↓
⤷ Start Trial
|
